Trial Profile
The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 01 Aug 2022 Results (n=134) published in the Archivos de Bronconeumologia.
- 14 Sep 2015 New trial record